BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

Voluntarily sign the informed consent and be expected to complete the follow-up examination and treatment of the study procedures. Subject, parent or legal guardian sign and date the informed consent form.

Age of 3-18 years old (inclusive of the cut-off value), regardless of gender and weight ≥10 kg.

Relapsed AML diagnostic criteria: the reappearance of peripheral blood or bone marrow blasts after complete remission (CR); 5% (excluding other causes such as bone marrow regrowth after consolidation chemotherapy) or extramedullary leukemic cell infiltration.

Refractory AML diagnostic criteria: newly diagnosed patients who failed to response to 2 courses of standard regimens; Patients who relapsed within 12 months after consolidation and intensive therapy; Patients relapsed after 12 months but failed to respond to conventional chemotherapy; Patients with two or more recurrences; Patients with persistent extramedullary leukemia.